Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 833

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 833
---
,398 |
| Thereafter                                                  | ​ | ​ |  8,874 |
| Total future minimum lease payments, undiscounted           | ​ |   | 14,371 |
| Less imputed interest                                       | ​ |   | -7,336 |
| Less lease incentive to be reimbursed                       | ​ | ​ |   -947 |
| Total                                                       | ​ | $ |  6,088 |
| ​                                                           | ​ | ​ |      ​ |
| Operating lease liability reported as of December 31, 2023: | ​ |   |        |
| Operating lease liability - current                         | ​ | $ |      — |
| Operating lease liability - non-current                     | ​ |   |  6,088 |
| Total                                                       | ​ | $ |  6,088 |

20. Legal Matters From time to time, the Company may become subject to arbitration, litigation or claims arising in the ordinary course of its business. The Company is not currently a party to any arbitration or legal proceeding that, if determined adversely to the Company, would have a material adverse effect on its business, operating results or financial condition. The results of any future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

F-83

<div align='center'>CARA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)</div>

21. Related Party Transactions As of December 31, 2023, Vifor International owned 616,397, or 13.6%, of the Company’s common stock. CSL Vifor and its affiliates are considered related parties as of December 31, 2023, 2022 and 2021 (see Note 13, Collaboration and Licensing Agreements). As of December 31, 2023 and 2022, amounts due from CSL Vifor of $ 2,765 and $ 3,260 , respectively, primarily relating to the Company’s share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor, its commercial supply of KORSUVA injection to CSL Vifor, and royalty payments from CSL Vifor were included within accounts receivable, net – related party. The Company’s collaborative revenue of $ 12,